MedPath

Assessing Closed-loop Insulin Delivery in Children With Type 1 Diabetes.

Not Applicable
Terminated
Conditions
Diabetes Mellitus, Type 1
Interventions
Other: Insulin-alone closed-loop
Registration Number
NCT04612257
Lead Sponsor
McGill University
Brief Summary

The objective of this clinical trial is to assess the safety of our insulin dosing algorithm in children with type 1 diabetes in a free-living study.

Detailed Description

This is a preliminary pilot study to generate data to optimize an insulin dosing algorithm to regulate glucose levels in children with type 1 diabetes. There will be up to two 40-hour test in outpatient settings, in which we will assess an insulin dosing algorithm. The two tests will allow us to compare different tunings in the same patient (this allows easier interpretation of the data). For example, if in a specific participant, the dosing algorithm reduced insulin delivery at night to avoid low blood glucose levesl but led to a rebound increase in glucose levels, then a second visit with a slightly different target range will help answer this question. The objective of this clinical trial is to assess the safety of our algorithm in children with type 1 diabetes in a free-living study.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
10
Inclusion Criteria
  1. Male or female children between 2 and 13 years of age.
  2. Clinical diagnosis of type 1 diabetes mellitus (the diagnosis of type 1 diabetes is based on the investigator's judgment).
  3. Using insulin pump therapy for at least 3 months
  4. For participants aged 7-13 years: Total daily insulin dose ≤ 40 units and 0.5 ≥ units/kg/day. For participants aged 2-6 years: Total daily insulin dose [8, 40] units and 0.3 ≥ units/kg/day.
  5. Most recent (in the last 6 months) HbA1c ≤ 12%.
Exclusion Criteria
  1. Using Medtronic 670G automated insulin delivery system (since participant's basal rates and insulin-to-carbohydrate ratios may reflect the use of 670G; generally overestimated by 20%).
  2. Severe hypoglycaemia or ketoacidosis episode ≤ two months before admission.
  3. Medical illness or other issues likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Insulin alone closed-loopInsulin-alone closed-loopInsulin alone closed-loop algorithm in children with type 1 diabetes in a free-living study.
Primary Outcome Measures
NameTimeMethod
Time in range40-hour intervention

Percentage of time of glucose levels spent in the target range (3.9-10.0 mmol/L).

Secondary Outcome Measures
NameTimeMethod
Specific nighttime time in range40-hour intervention

Percentage of time (00:00-6:00) of glucose levels spent a. below 3.9 mmol/L; b. between 3.9 and 7.8 mmol/L; c. between 3.9 and 10.0 mmol/L; d. below 3.3 mmol/L; e. below 2.8 mmol/L; f. above 10.0 mmol/L; g. above 13.9 mmol/L; h. above 16.7 mmol/L.

Coefficient of variance of glucose levels and insulin delivery40-hour intervention

Coefficient of variance of glucose levels and insulin delivery.

Mean glucose levels40-hour intervention

Mean glucose levels.

Specific time in range40-hour intervention

Percentage of time of glucose levels spent a. between 3.9 and 7.8 mmol/L; b. below 3.9 mmol/L; c. below 3.3 mmol/L; d. below 2.8 mmol/L; e. above 10.0 mmol/L; f. above 13.9 mmol/L; g. above 16.7 mmol/L.

Standard deviation of glucose levels and insulin delivery40-hour intervention

Standard deviation of glucose levels and insulin delivery.

Total insulin delivery40-hour intervention

Total amount of insulin delivered.

Trial Locations

Locations (1)

McGill University Health Centre Research Institute

🇨🇦

Montréal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath